

Jonathan E Alpert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4470289/publications.pdf>

Version: 2024-02-01

204
papers

13,783
citations

17440

63
h-index

22832

112
g-index

214
all docs

214
docs citations

214
times ranked

10308
citing authors

#	ARTICLE	IF	CITATIONS
1	Connection During COVID-19: Pilot Study of a Telehealth Group Parenting Intervention. American Journal of Psychotherapy, 2022, 75, 67-74.	1.2	8
2	Mobilizing a psychiatric crisis response to COVID-19 for NYC hospital workers: Lessons learned from the mental health front lines. General Hospital Psychiatry, 2022, 74, 141-143.	2.4	1
3	Climate change and mental health research methods, gaps, and priorities: a scoping review. Lancet Planetary Health, The, 2022, 6, e281-e291.	11.4	41
4	Ethical and Safe Discharges from Psychiatric Units during the COVID-19 Pandemic.. Journal of the American Academy of Psychiatry and the Law, 2022, , .	0.2	0
5	A Bronx tale: Exposure, containment and care on inpatient psychiatry units during COVID-19. General Hospital Psychiatry, 2021, 69, 121-123.	2.4	11
6	A vote for the full ticket. Bipolar Disorders, 2021, 23, 88-89.	1.9	0
7	Psychopharmacology and Neurotherapeutics. , 2021, , 342-388.		0
8	Disorders Related to Stress and Trauma. , 2021, , 166-178.		0
9	Feeding and Eating Disorders. , 2021, , 289-317.		0
10	Health Policy and Population Health in Behavioral Health Care in the United States. , 2021, , 473-485.		0
11	Psychosocial Interventions. , 2021, , 389-414.		0
12	Neurocognitive Disorders. , 2021, , 263-288.		0
13	Introduction to the Patient Interview. , 2021, , 38-69.		0
14	Global Health and Mental Health Care Delivery in Low-Resource Settings. , 2021, , 486-496.		0
15	Child Psychiatry and Neurodevelopmental Disorders. , 2021, , 318-328.		0
16	Psychiatry of Gender and Sexuality. , 2021, , 448-472.		0
17	Obsessive-Compulsive and Related Disorders. , 2021, , 146-165.		0
18	Psychiatric Evaluation in the Medical Setting. , 2021, , 415-447.		0

#	ARTICLE	IF	CITATIONS
19	Schizophrenia Spectrum and Other Psychotic Disorders. , 2021, , 102-127.		0
20	Clinical Neuroscience. , 2021, , 9-37.		0
21	Letter to the Editor: New onset psychosis and mania following COVID-19 infection. Journal of Psychiatric Research, 2020, 130, 177-179.	3.1	50
22	Stretching beyond the evidence base. Bipolar Disorders, 2020, 22, 418-419.	1.9	0
23	Depression Treatment Expenditures for Adults in the USA: a Systematic Review. Current Psychiatry Reports, 2019, 21, 105.	4.5	13
24	Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. Journal of Affective Disorders, 2019, 243, 516-524.	4.1	120
25	The Effects of Tai Chi on Sleep Quality in Chinese American Patients With Major Depressive Disorder: A Pilot Study. Behavioral Sleep Medicine, 2018, 16, 398-411.	2.1	13
26	Outcomes of an online computerized cognitive behavioral treatment program for treating chinese patients with depression: A pilot study. Asian Journal of Psychiatry, 2018, 38, 102-107.	2.0	19
27	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomedicine and Laser Surgery, 2018, 36, 634-646.	2.0	73
28	A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain. Journal of Clinical Psychiatry, 2018, 79, 26-34.	2.2	23
29	Inflammatory cytokines in major depressive disorder: A caseâ€“control study. Australian and New Zealand Journal of Psychiatry, 2017, 51, 23-31.	2.3	60
30	A Pilot, Randomized Controlled Study of Tai Chi With Passive and Active Controls in the Treatment of Depressed Chinese Americans. Journal of Clinical Psychiatry, 2017, 78, e522-e528.	2.2	30
31	Obsessive-Compulsive Symptoms as a Risk Factor for Suicidality in U.S. College Students. Journal of Adolescent Health, 2016, 58, 481-484.	2.5	20
32	The Effectiveness of Telepsychiatry-Based Culturally Sensitive Collaborative Treatment for Depressed Chinese American Immigrants. Journal of Clinical Psychiatry, 2016, 77, e996-e1002.	2.2	23
33	Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine. Journal of Clinical Psychiatry, 2016, 77, e719-e725.	2.2	100
34	Association Between Stigma and Depression Outcomes Among Chinese Immigrants in a Primary Care Setting. Journal of Clinical Psychiatry, 2016, 77, e1287-e1292.	2.2	19
35	The Role of Anger/Hostility in Treatment-Resistant Depression. Journal of Nervous and Mental Disease, 2015, 203, 762-768.	1.0	19
36	Treatment Outcome in Depressed Latinos Predicted by Concomitant Psychosislike Symptoms. Journal of Nervous and Mental Disease, 2015, 203, 769-773.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in Clinical Neuroscience, 2015, 17, 111-126.	3.7	149
38	Geriatric Psychopharmacology: Pharmacokinetic and Pharmacodynamic Considerations. Psychiatric Annals, 2015, 45, .	0.1	1
39	Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). CNS Spectrums, 2014, 19, 535-546.	1.2	27
40	How to Get Help With Starting Your Research Project: ADMSEP Task Force on Research and Scholarship. Academic Psychiatry, 2013, 37, 221.	0.9	2
41	Increased GsM within blood cell membrane lipid microdomains in some depressive disorders: An exploratory study. Journal of Psychiatric Research, 2013, 47, 706-711.	3.1	8
42	Interprofessional Differences in Disposition Decisions: Results From a Standardized Web-Based Patient Assessment. Psychiatric Services, 2013, 64, 808-811.	2.0	9
43	Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2013, 33, 827-830.	1.4	3
44	L-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials. American Journal of Psychiatry, 2012, 169, 1267-1274.	7.2	229
45	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectrums, 2012, 17, 76-86.	1.2	15
46	SAME and sexual functioning. European Psychiatry, 2012, 27, 451-454.	0.2	29
47	Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. European Psychiatry, 2012, 27, 518-521.	0.2	14
48	Cognitive therapy for anxious depression in STAR*D: What have we learned?. Journal of Affective Disorders, 2012, 142, 213-218.	4.1	41
49	Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Journal of Affective Disorders, 2012, 136, 1174-1178.	4.1	40
50	Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder. CNS Neuroscience and Therapeutics, 2012, 18, 441-451.	3.9	38
51	Bioavailability of S-Adenosyl Methionine and Impact on Response in a Randomized, Double-Blind, Placebo-Controlled Trial in Major Depressive Disorder. Journal of Clinical Psychiatry, 2012, 73, 843-848.	2.2	27
52	Assessing anxious features in depressed outpatients. International Journal of Methods in Psychiatric Research, 2011, 20, e69-82.	2.1	16
53	Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2011, 168, 593-602.	7.2	149
54	S-Adenosyl Methionine (SAME) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial. American Journal of Psychiatry, 2010, 167, 942-948.	7.2	275

#	ARTICLE	IF	CITATIONS
55	Site Versus Centralized Raters in a Clinical Depression Trial. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 193-197.	1.4	57
56	Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. <i>International Clinical Psychopharmacology</i> , 2010, 25, 214-217.	1.7	34
57	Psychiatric OSCE Performance of Students With and Without a Previous Core Psychiatry Clerkship. <i>Academic Psychiatry</i> , 2010, 34, 141-144.	0.9	8
58	An Approach to the Psychopharmacologic Care of Patients: Antidepressants, Antipsychotics, Anxiolytics, Mood Stabilizers, and Natural Remedies. <i>Medical Clinics of North America</i> , 2010, 94, 1141-1160.	2.5	11
59	Cognitive-Behavioral Therapy for Patients With Parkinson's Disease and Comorbid Major Depressive Disorder. <i>Psychosomatics</i> , 2010, 51, 124-129.	2.5	43
60	Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report. <i>CNS Spectrums</i> , 2009, 14, 487-498.	1.2	10
61	Monoamine Oxidase A and Catechol-O-Methyltransferase Functional Polymorphisms and the Placebo Response in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 372-377.	1.4	98
62	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 282-289.	4.5	81
63	Adverse Endocrine and Metabolic Effects of Psychotropic Drugs. <i>CNS Drugs</i> , 2009, 23, 1003-1021.	5.9	83
64	Frontal EEG predictors of treatment outcome in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2009, 19, 772-777.	0.7	158
65	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009, 50, 448-454.	2.5	6
66	A Double-Blind, Randomized Controlled Trial of Ethyl-Eicosapentaenoate for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1636-1644.	2.2	79
67	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. <i>Journal of Youth and Adolescence</i> , 2008, 37, 906-916.	3.5	81
68	Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 271-276.	4.5	29
69	Family history of completed suicide and characteristics of major depressive disorder: A STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Affective Disorders</i> , 2008, 108, 129-134.	4.1	16
70	Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. <i>Journal of Psychiatric Research</i> , 2008, 42, 134-140.	3.1	34
71	Enhanced norepinephrine output during long-term desipramine treatment: A possible role for the extraneuronal monoamine transporter (SLC22A3). <i>Journal of Psychiatric Research</i> , 2008, 42, 605-611.	3.1	20
72	Vagus Nerve Stimulation: 2-Year Outcomes for Bipolar Versus Unipolar Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2008, 64, 455-460.	1.3	83

#	ARTICLE	IF	CITATIONS
73	A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. European Neuropsychopharmacology, 2008, 18, 639-645.	0.7	73
74	Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms. Journal of Clinical Child and Adolescent Psychology, 2008, 37, 714-724.	3.4	60
75	Antecedentes familiares de suicidio consumado y características del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). Psiquiatría Biológica, 2008, 15, 195-201.	0.1	0
76	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. American Journal of Psychiatry, 2008, 165, 342-351.	7.2	741
77	Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2008, 165, 1136-1147.	7.2	169
78	Depression Outcomes of Spanish- and English-Speaking Hispanic Outpatients in STAR*D. Psychiatric Services, 2008, 59, 1273-1284.	2.0	26
79	A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders. Journal of Clinical Psychopharmacology, 2008, 28, 660-666.	1.4	59
80	Hopelessness as a Predictor of Non-Response to Fluoxetine in Major Depressive Disorder. Annals of Clinical Psychiatry, 2007, 19, 5-8.	0.6	20
81	Ethnicity/Race and Outcome in the Treatment of Depression. Medical Care, 2007, 45, 1043-1051.	2.4	54
82	Major Depressive Disorder with Anger Attacks and Cardiovascular Risk Factors. International Journal of Psychiatry in Medicine, 2007, 37, 99-111.	1.8	16
83	Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Research, 2007, 149, 195-200.	3.3	27
84	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. Psychosomatics, 2007, 48, 418-425.	2.5	30
85	Does Psychiatry Residency Training Reflect the "Real World" of Psychiatry Practice? A Survey of Residency Graduates. Academic Psychiatry, 2007, 31, 281-289.	0.9	12
86	Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD. Depression and Anxiety, 2007, 24, 433-439.	4.1	17
87	Preadult onset vs. adult onset of major depressive disorder: a replication study. Acta Psychiatrica Scandinavica, 2007, 115, 196-205.	4.5	62
88	Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STAR*D trial. Journal of Affective Disorders, 2007, 97, 77-84.	4.1	71
89	Remission of maternal depression and child symptoms among single mothers. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 962-971.	3.1	28
90	A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatric Disease and Treatment, 2007, 3, 169-172.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Getting Our Own House in Order: Improving Psychiatry Education to Medical Students as a Prelude to Medical School Education Reform. <i>Academic Psychiatry</i> , 2006, 30, 170-173.	0.9	6
92	Virtual Reality, Telemedicine, Web and Data Processing Innovations in Medical and Psychiatric Education and Clinical Care. <i>Academic Psychiatry</i> , 2006, 30, 528-533.	0.9	36
93	Somatic Symptoms in Outpatients With Major Depressive Disorder Treated With Fluoxetine. <i>Psychosomatics</i> , 2006, 47, 348-352.	2.5	21
94	Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine. <i>Biological Psychiatry</i> , 2006, 60, 270-274.	1.3	29
95	Enrolling research subjects from clinical practice: Ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. <i>Psychiatry Research</i> , 2006, 141, 193-200.	3.3	21
96	Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 1542-1548.	7.2	95
97	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 823-835.	1.9	148
98	A Survey of Antidepressant Prescribing Practices in Major Depression with Comorbid Attention-Deficit Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 216-218.	1.4	0
99	Remissions in Maternal Depression and Child Psychopathology. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1389.	7.4	539
100	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161-1172.	7.2	233
101	A Comparison of Lithium and T ₃ Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1519-1530.	7.2	526
102	Improving depression outcome: new concepts, strategies and technologies. <i>Journal of Psychopharmacology</i> , 2006, 20, 3-4.	4.0	3
103	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161.	7.2	167
104	Children of Currently Depressed Mothers. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 126-136.	2.2	123
105	A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1754-1759.	2.2	181
106	Outcomes of Recognizing Depressed Chinese American Patients in Primary Care. <i>International Journal of Psychiatry in Medicine</i> , 2005, 35, 213-224.	1.8	12
107	Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 215-221.	2.1	14
108	The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 523.	2.1	81

#	ARTICLE	IF	CITATIONS
109	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 441-447.	1.4	116
110	Personality Disorders and the Tridimensional Personality Questionnaire Factors in Major Depressive Disorder. <i>Journal of Nervous and Mental Disease</i> , 2005, 193, 747-750.	1.0	8
111	Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder. <i>Psychosomatic Medicine</i> , 2005, 67, 703-706.	2.0	55
112	Obesity among outpatients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 59-63.	2.1	89
113	The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. <i>International Clinical Psychopharmacology</i> , 2005, 20, 87-91.	1.7	26
114	Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 425-433.	4.5	157
115	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 301-307.	1.8	35
116	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 291-299.	1.8	28
117	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>Focus (American Journal of Psychiatry)</i> , 2005, 113, 1078-1084.	1.0	14
118	Relationships between major depressive disorder and comorbid anxiety and personality disorders. <i>Comprehensive Psychiatry</i> , 2005, 46, 266-271.	3.1	32
119	The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD). <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 465-470.	4.5	39
120	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004, 25, 119-142.	1.9	898
121	Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. <i>Psychiatry Research</i> , 2004, 126, 287-290.	3.3	19
122	Factors that differentiate early vs. later onset of major depression disorder. <i>Psychiatry Research</i> , 2004, 129, 127-140.	3.3	121
123	Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. <i>Psychosomatics</i> , 2004, 45, 224-229.	2.5	25
124	Comorbid Medical Illness and Relapse of Major Depressive Disorder in the Continuation Phase of Treatment. <i>Psychosomatics</i> , 2004, 45, 419-425.	2.5	48
125	Psychosocial functioning in patients with treatment resistant depression. <i>European Psychiatry</i> , 2004, 19, 196-201.	0.2	29
126	Serum Cholesterol in the Continuation Phase of Pharmacotherapy With Fluoxetine in Remitted Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 467-469.	1.4	10

#	ARTICLE	IF	CITATIONS
127	Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine. Journal of Clinical Psychopharmacology, 2004, 24, 507-511.	1.4	57
128	S-Adenosyl-L-Methionine (SAME) as an Adjunct for Resistant Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2004, 24, 661-664.	1.4	97
129	Reply to Comments by Drs. Bschor and Bauer. Journal of Clinical Psychopharmacology, 2004, 24, 241-242.	1.4	0
130	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychological Medicine, 2004, 34, 1299-1308.	4.5	352
131	Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychological Medicine, 2004, 34, 555-561.	4.5	29
132	The Overlap Between Personality Disorders and Major Depressive Disorder (MDD). Annals of Clinical Psychiatry, 2004, 16, 217-224.	0.6	19
133	Ziprasidone Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) for SSRI-Resistant Major Depressive Disorder. Journal of Clinical Psychiatry, 2004, 65, 217-221.	2.2	127
134	Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in Major Depressive Disorder. Journal of Clinical Psychiatry, 2004, 65, 543-546.	2.2	30
135	Gepirone Extended-Release Treatment of Anxious Depression. Journal of Clinical Psychiatry, 2004, 65, 1069-1075.	2.2	20
136	Serum Folate, Vitamin B12, and Homocysteine in Major Depressive Disorder, Part 1. Journal of Clinical Psychiatry, 2004, 65, 1090-1095.	2.2	88
137	Serum Folate, Vitamin B12, and Homocysteine in Major Depressive Disorder, Part 2. Journal of Clinical Psychiatry, 2004, 65, 1096-1098.	2.2	59
138	Psychopharmacologic Issues in the Medical Setting. , 2004, , 231-267.		1
139	Funcionamiento psicosocial en pacientes con depresi3n resistente al tratamiento. European Psychiatry (Ed Espa±ola), 2004, 11, 508-513.	0.0	0
140	Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Journal of Clinical Psychiatry, 2004, 65, 1069-75.	2.2	3
141	S-adenosyl-methionine in depression: A comprehensive review of the literature. Current Psychiatry Reports, 2003, 5, 460-466.	4.5	87
142	Teaching ethics of psychopharmacology research in psychiatric residency training programs. Psychopharmacology, 2003, 171, 105-111.	3.1	13
143	Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder. Annals of Clinical Psychiatry, 2003, 15, 187-192.	0.6	4
144	Early-onset depression and the emotional and behavioral characteristics of offspring. Depression and Anxiety, 2003, 18, 104-108.	4.1	2

#	ARTICLE	IF	CITATIONS
145	Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20â€¢mg/day. Acta Psychiatrica Scandinavica, 2003, 108, 432-438.	4.5	22
146	Somatic symptoms in treatment-resistant depression. Psychiatry Research, 2003, 118, 39-45.	3.3	46
147	Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Research, 2003, 118, 137-145.	3.3	52
148	Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Research, 2003, 118, 183-188.	3.3	26
149	Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Comprehensive Psychiatry, 2003, 44, 44-50.	3.1	15
150	Serum Cholesterol in Treatment-Resistant Depression. Neuropsychobiology, 2003, 47, 146-151.	1.9	41
151	Behavioral and Emotional Disturbances in the Offspring of Depressed Parents with Anger Attacks. Psychotherapy and Psychosomatics, 2003, 72, 102-106.	8.8	20
152	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. American Journal of Psychiatry, 2003, 160, 2122-2127.	7.2	109
153	A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. International Clinical Psychopharmacology, 2003, 18, 293-296.	1.7	5
154	Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants. Journal of Clinical Psychopharmacology, 2003, 23, 92-95.	1.4	90
155	Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder. Annals of Clinical Psychiatry, 2003, 15, 187-192.	0.6	2
156	Nortriptyline for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2003, 64, 35-39.	2.2	139
157	Folinic Acid (Leucovorin) as an Adjunctive Treatment for SSRI-Refractory Depression. Annals of Clinical Psychiatry, 2002, 14, 33-38.	0.6	87
158	Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2002, 22, 474-480.	1.4	63
159	Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine. Journal of Clinical Psychopharmacology, 2002, 22, 379-387.	1.4	114
160	Personality disorders and depression. Psychological Medicine, 2002, 32, 1049-1057.	4.5	100
161	PREDICTORS OF STABLE PERSONALITY DISORDER DIAGNOSES IN OUTPATIENTS WITH REMITTED DEPRESSION. Journal of Nervous and Mental Disease, 2002, 190, 248-256.	1.0	13
162	Melancholia and axis II comorbidity. Comprehensive Psychiatry, 2002, 43, 331-335.	3.1	18

#	ARTICLE	IF	CITATIONS
163	NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. <i>Psychiatry Research</i> , 2002, 109, 9-16.	3.3	34
164	A survey of prescribing practices in the treatment of depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 177-187.	4.8	62
165	Body dysmorphic disorder in outpatients with major depression. <i>Journal of Affective Disorders</i> , 2002, 69, 141-148.	4.1	57
166	Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 33-38.	0.6	44
167	Strengthening clinical effectiveness trials: Equipoise-stratified randomization. <i>Biological Psychiatry</i> , 2001, 50, 792-801.	1.3	144
168	Use of the five-factor inventory in characterizing patients with major depressive disorder. <i>Comprehensive Psychiatry</i> , 2001, 42, 488-493.	3.1	43
169	Psychiatric comorbidity in treatment-resistant depression. , 2001, , 430-478.		2
170	T3 Blood Levels and Treatment Outcome in Depression. <i>International Journal of Psychiatry in Medicine</i> , 2001, 31, 367-373.	1.8	12
171	Management of Major Depression in the Primary Care Setting. <i>Psychotherapy and Psychosomatics</i> , 2001, 70, 103-107.	8.8	24
172	Tryptophan depletion in SSRI-recovered depressed outpatients. <i>Psychopharmacology</i> , 2001, 155, 123-127.	3.1	75
173	Nutrition and depression: focus on folate. <i>Nutrition</i> , 2000, 16, 544-546.	2.4	138
174	Timing of Onset of Antidepressant Response With Fluoxetine Treatment. <i>American Journal of Psychiatry</i> , 2000, 157, 1423-1428.	7.2	207
175	Fenfluramine challenge in unipolar depression with and without anger attacks. <i>Psychiatry Research</i> , 2000, 94, 9-18.	3.3	79
176	Anxiety disorders in major depression. <i>Comprehensive Psychiatry</i> , 2000, 41, 97-102.	3.1	275
177	Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. <i>Journal of Psychosomatic Research</i> , 2000, 49, 183-187.	2.6	26
178	DEPRESSIVE BREAKTHROUGH. <i>Psychiatric Clinics of North America</i> , 2000, 23, 731-742.	1.3	18
179	Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. <i>Journal of Affective Disorders</i> , 1999, 52, 217-223.	4.1	30
180	Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. <i>Biological Psychiatry</i> , 1999, 46, 202-211.	1.3	62

#	ARTICLE	IF	CITATIONS
181	Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 329-335.	1.4	51
182	Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 221-225.	2.2	395
183	Signal Transduction by Platelet Adenylate Cyclase: Alterations in Depressed Patients May Reflect Impairment in the Coordinated Integration of Cellular Signals (Coincidence Detection) 11This work was presented in part at the Annual Meeting of the American Psychiatric Association, New York, NY, May 7, 1996.. <i>Biological Psychiatry</i> , 1998, 43, 574-583.	1.3	19
184	Outcome Definitions and Predictors in Depression. <i>Psychotherapy and Psychosomatics</i> , 1998, 67, 266-270.	8.8	75
185	Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine. <i>American Journal of Psychiatry</i> , 1997, 154, 1760-1762.	7.2	167
186	Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. <i>Psychological Medicine</i> , 1997, 27, 627-633.	4.5	92
187	PSYCHOTHERAPEUTIC APPROACHES TO AGGRESSIVE AND VIOLENT PATIENTS. <i>Psychiatric Clinics of North America</i> , 1997, 20, 453-472.	1.3	33
188	Major depressive subtypes and treatment response. <i>Biological Psychiatry</i> , 1997, 42, 568-576.	1.3	222
189	Nutrition and Depression: The Role of Folate. <i>Nutrition Reviews</i> , 1997, 55, 145-149.	5.8	148
190	Are study dropouts different from completers?. <i>Biological Psychiatry</i> , 1996, 40, 668-670.	1.3	25
191	Gender differences in Axis I comorbidity among depressed outpatients. <i>Journal of Affective Disorders</i> , 1996, 38, 129-133.	4.1	49
192	Attention deficit hyperactivity disorder in childhood among adults with major depression. <i>Psychiatry Research</i> , 1996, 62, 213-219.	3.3	107
193	Fluoxetine Treatment of Anger Attacks: A Replication Study. <i>Annals of Clinical Psychiatry</i> , 1996, 8, 7-10.	0.6	36
194	Hostility changes following antidepressant treatment: Relationship to stress and negative thinking. <i>Journal of Psychiatric Research</i> , 1996, 30, 459-467.	3.1	27
195	Childhood psychopathology retrospectively assessed among adults with early onset major depression. <i>Journal of Affective Disorders</i> , 1994, 31, 165-171.	4.1	53
196	Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. <i>Brain Research</i> , 1986, 363, 145-147.	2.2	71
197	Aversive effects of subcutaneously injected vasopressin in the rat: independence of the ascending dorsal noradrenergic bundle. <i>Brain Research</i> , 1985, 337, 133-137.	2.2	4
198	Impairment in T-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats. <i>Behavioural Brain Research</i> , 1984, 13, 63-70.	2.2	121

#	ARTICLE	IF	CITATIONS
199	Dopamine denervation of frontal cortex or nucleus accumbens does not affect acth-induced grooming behaviour. Behavioural Brain Research, 1984, 12, 307-315.	2.2	17
200	Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones. Nature, 1983, 306, 791-792.	27.8	153
201	CCK-8 modulation of mesolimbic dopamine: Antagonism of amphetamine-stimulated behaviors. Peptides, 1983, 4, 749-753.	2.4	75
202	The effects of central catecholamine depletions on spatial learning in rats. Behavioural Brain Research, 1983, 9, 83-104.	2.2	104
203	Amphetamine and maternal behavior: Dose response relationships. Psychopharmacology, 1980, 70, 195-199.	3.1	17
204	Maternal care received by rat pups treated with 6-hydroxydopamine. Physiology and Behavior, 1979, 22, 69-75.	2.1	7